Archives
-
COVID-19: 100% Survival Rate Therapy of Israeli-based Pluristem Tested on US patient
The Israeli-based Pluristem Therapeutics Inc. announced on April 13 that it has treated its first American patient suffering from COVID-19 complications in the United States under the U.S. Food and Drug Administration (FDA) Single Patient Expanded Access Program or compassionate program.
Latest Research Articles
-
Sweden is Trying to Beat the COVID-19 Pandemic Without Complete Lockdown
-
Baby's Gender Depends on Father's Genes, Study Says
-
What Does Single Touch Payroll Mean For Employees
-
Preliminary Discovery: First 'Significant' SARS-CoV-2 Mutation
-
African-Americans Most Likely to Get COVID-19: Here Are Reasons Why
-
Quarantine Binge Drinking May End Badly
-
Ten Previously Thought Extinct Apple Varieties Found Again in Pacific Northwest
-
The Evolution of Rain’s Distinct Scent and Its Role in Bacterial Propagation
-
Ideal Gaming Gift Gadgets This Season For Your Loved Ones
-
Study: Amazonian Regions were Agricultural Landscapes Some 10,000 Years Ago
Wild Dolphins Apparently Have a Range of Personalities
-
Scientists: Dogs May Detect the Coronavirus in Humans
MOST POPULAR
-
Coral Bleaching Crisis: How Ocean Warming Threatens Marine Ecosystems Worldwide
-
Met Office Issues Warning About Thunderstorms And Flooding: Are They Coming To A Place Near You?
-
Are Orcas Friendly to Humans? Killer Whales Mysteriously Attack Boats in Portugal, Even Sinking One
-
Orca Attack Video: Yacht Sinks In Portugal In Viral Clip - How Strong Are These Ocean Predators?
-
Bangkok Sink Hole Shocks The World: Here Are Other Deadly Incidents That Happened And Why
